v3.23.3
Collaborations (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Collaborative and license agreements          
AbbVie's receivable from Janssen $ 11,412   $ 11,412   $ 11,254
AbbVie's payable to Janssen 29,658   29,658   25,402
Janssen Biotech Inc. | Collaborative arrangement          
Collaborative and license agreements          
Milestone payments 200   $ 200    
Share of collaboration development costs responsible by Janssen (as a percent)     60.00%    
Share of collaboration development costs responsible by the entity (as a percent)     40.00%    
Global - AbbVie's share of other costs (included in respective line items) 59 $ 63 $ 171 $ 196  
AbbVie's receivable from Janssen 253   253   295
AbbVie's payable to Janssen 308   308   $ 379
Janssen Biotech Inc. | Collaborative arrangement | United States          
Collaborative and license agreements          
Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold) 316 398 925 1,210  
Janssen Biotech Inc. | Collaborative arrangement | International          
Collaborative and license agreements          
International - AbbVie's share of profits (included in net revenues) 230 286 711 868  
Genentech, Inc. | Collaborative arrangement          
Collaborative and license agreements          
Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold) 225 204 641 578  
AbbVie's share of development costs (included in R&D) 24 29 82 87  
Genentech, Inc. | Collaborative arrangement | United States          
Collaborative and license agreements          
AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A) $ 13 $ 10 $ 32 $ 27